Commentary on Hey and Kimmelman

Hey SP Kimmelman J . Are outcome-adaptive allocation trials ethical? Clin Trials 2015, 12: 102–106.

Heilig CM Weijerb C . A critical history of individual and collective ethics in the lineage of Lellouch and Schwartz. Clin Trials 2005; 2: 244–253.

Hey SP Kimmelman J . The questionable use of unequal allocation in confirmatory trials. Neurology 2014; 82: 77–79.

Hu F Rosenberger WF . The theory of response-adaptive randomization in clinical trials. New York: Wiley, 2006.

Berry DA . Adaptive clinical trials: the promise and the caution. J Clin Oncol 2011; 29: 606–609.

Rosenberger WF Lachin J . Randomization in clinical trials. New York: Wiley, 2002.

Thall PF Fox P Wathen JK . Some caveats for outcome adaptive randomization in clinical trials. In: Sverdlov O (ed.) Modern adaptive randomized clinical trials: statistical, operational, and regulatory aspects. Taylor & Francis, in press.

Maki RG Wathen JK Patel SR . Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol 2007; 25: 2755–2763.

Zhou X Liu S Kim ES . Bayesian adaptive design for targeted therapy development in lung cancer—a step toward personalized medicine. Clin Trials 2008; 5: 181–193.

Barker AD Sigman CC Kelloff GJ . I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97–100.

Korn EL Freidlin B . Outcome-adaptive randomization: is it useful? J Clin Oncol 2011; 29: 771–776.